In their study, MASLD patients complicated with type 2 diabetes treated with pemafibrate for >1 year were included, in whom prior treatment with an SGLT2i >1 year failed to normalize serum ALT levels [152]. This evidence concerns the gene GPT and type 2 diabetes mellitus.